Preclinical studies have shown that MSCs can suppress tumor growth and metastasis by suppressing tumor angiogenesis through the release of antiangiogenic factors in models of lung metastasis, melanoma, colon cancer, prostate cancer, and ovarian cancer, and MSC also mediated downregulation of the PDGF/PDGFR axis, suppressing glioma angiogenesis [11,12]. The gene discussed is PDGFRB; the disease is neoplasm.